Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Neurogastroenterol Motil. 2021 Apr 2;33(12):e14145. doi: 10.1111/nmo.14145

FIGURE 2.

FIGURE 2.

Simulations assessing the proportion of respondents who would prefer a SQ-administered medicine over an oral therapy across a range of efficacy levels, keeping all other factors the same (e.g., risk of side effects). For example, 66.0% of individuals would choose a SQ therapy that decreases pain by 70% within 1 hour when compared to an oral option that reduces pain by only 30%.